New Launch23 Oct 2025, 09:23 am
Glenmark Pharmaceuticals Inc., USA to launch Ropivacaine Hydrochloride Injection USP with $20.9 million market
AI Summary
Glenmark Pharmaceuticals Inc., USA (Glenmark) has announced the upcoming launch of Ropivacaine Hydrochloride Injection USP, 40 mg/20 mL (2mg/mL), 150 mg/30 mL (5 mg/mL), and 200 mg/20 mL (10 mg/mL) Single-Dose Vials in November 2025. The product is bioequivalent and therapeutically equivalent to the reference listed drug, Naropin® Injection, of Fresenius Kabi USA, LLC. The Naropin® Injection market achieved annual sales of approximately $20.9 million as per IQVIA® sales data for the 12-month period ending August 2025. This launch marks an important addition to Glenmark’s expanding injectable portfolio, reinforcing the company's commitment to bring quality and affordable alternatives to market for patients in need.
Key Highlights
- Glenmark Pharmaceuticals Inc., USA to launch Ropivacaine Hydrochloride Injection USP, 40 mg/20 mL (2mg/mL), 150 mg/30 mL (5 mg/mL), and 200 mg/20 mL (10 mg/mL) Single-Dose Vials in November 2025.
- The product is bioequivalent and therapeutically equivalent to the reference listed drug, Naropin® Injection, of Fresenius Kabi USA, LLC.
- The Naropin® Injection market achieved annual sales of approximately $20.9 million as per IQVIA® sales data for the 12-month period ending August 2025.
- This launch marks an important addition to Glenmark’s expanding injectable portfolio.
- The launch reinforces Glenmark’s commitment to bring quality and affordable alternatives to market for patients in need.